Your prediction
Cerenis Therapeutics Holding S.A. Stock
The Cerenis Therapeutics Holding S.A. stock is trending slightly upwards today, with an increase of €0.015 (0.420%) compared to yesterday's price.
Our community identified positive and negative aspects for Cerenis Therapeutics Holding S.A. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Cerenis Therapeutics Holding S.A. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
B****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | 0.420% | -7.292% | 16.150% | 200.676% | 3.790% | 100.450% | 265.879% |
| Sensorion SA | -0.790% | -5.000% | 1.877% | - | - | - | - |
| Genoway S.A. Inh. | -0.860% | 1.304% | -1.688% | -14.338% | -6.048% | -37.867% | -29.819% |
| Hybrigenics S.A. | 191.670% | -7.692% | -14.286% | -61.290% | -7.692% | -95.737% | -98.972% |
News
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced